Study Evaluating the Safety of Enbrel (Etanercept)

The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.

Completed

Looking for future studies?

Key information

Conditions

Arthritis, Psoriatic Arthritis Bone Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Sex eligibility

All sexes

Study type

Observational

Primary location

Metro Manila, Philippines

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients from the study center who received or will receive at least one dose of Enbrel according to the approved product indication.

Exclusion criteria

Previously discontinued Enbrel therapy due to significant safety concern.

Treatment and study plan

Etanercept (Enbrel)

Drug

Primary outcomes

Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection

Time frame: 30 days post injection up to 3 years

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Etanercept (Enbrel) 25 mg by Subcutaneous Injection

Important dates

Study start: 2007
Primary completion: 2009
Study completion: 2009
First posted: May 23, 2008
Registry last updated: Nov 16, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed